Results 91 to 100 of about 7,117 (221)

Managing Pharmacotherapy in People Living With HIV and Concomitant Malignancy. [PDF]

, 2019
Objective: To describe data with selected malignancies in people living with HIV (PLWH) and HIV in individuals affected by both conditions and to summarize drug-drug interactions (DDIs) with clinical recommendations for point-of-care review of ...
Chan, Alexandre, Klibanov, Olga, Olin, Jacqueline L, Spooner, Linda M   +3 more
core   +1 more source

The expression and signalling patterns of CD180 toll like receptor in Chronic Lymphocytic Leukaemia (CLL) [PDF]

, 2019
Chronic lymphocytic leukaemia (CLL) is characterised by a progressive accumulation of mature CD5+CD20+CD23+ lymphocytes. Despite the remarkable progress in our understanding of the immunobiology of CLL, the aetiology of the disease remains unknown.
Sayed, U., Sayed, U.
core  

A matching‐adjusted indirect comparison of survival outcomes with pirtobrutinib (BRUIN) versus standard of care (SCHOLAR‐2) in relapsed/refractory mantle cell lymphoma previously treated with a covalent Bruton tyrosine kinase inhibitor

British Journal of Haematology, Volume 208, Issue 1, Page 312-316, January 2026.
Georg Heß, Toby A. Eyre, Min‐Hua Jen, Jiewen Zhang, Benjamin Goebel, Sarang Abhyankar, Martin Dreyling   +6 more
wiley   +1 more source

Upfront Management of Blastoid Variant Mantle Cell Lymphoma: Making the Case for 2nd/3rd-Generation Bruton Tyrosine Kinase Inhibitor-Based Therapies. [PDF]

INTRODUCTION: Blastoid variant-mantle cell lymphoma (BV-MCL) represents an aggressive subset of patients with no established standard of care treatment approach.
Brem, Elizabeth, Ciurea, Stefan, Doh, Jean, Griffin, Shawn, Kongtim, Piyanuch, Lee, Benjamin, Liu, Jenny   +6 more
core   +1 more source

Final results and overall survival data from a phase II study of acalabrutinib monotherapy in patients with relapsed/refractory mantle cell lymphoma, including those with poor prognostic factors [PDF]

No abstract ...
Calvo R., Davies A. J., Dlugosz-Danecka M., Doorduijn J. K., Eek R., Goy A., Jacobsen E., Jain P., Kater A. P., Le Gouill S., Panizo C., Robak T., Rule S., Shah B. D., Smith S. D., Tao L., Wang M., Zinzani P. L.   +17 more
core   +4 more sources

Analysis of ventricular arrhythmias and sudden death from prospective, randomized clinical trials of acalabrutinib [PDF]

This analysis investigated the incidence of sudden deaths (SDs) and non-fatal and fatal ventricular arrhythmias (VAs) in five acalabrutinib clinical trials. In total, 1299 patients received acalabrutinib (exposure, 4568.4 patient-years).
Bajwa N., Ghia P., Miranda P., Rule S., Seymour J. F., Sharman J. P., Shaw B.   +6 more
core   +1 more source

Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib. [PDF]

, 2019
The Bruton tyrosine kinase (BTK) inhibitor ibrutinib improves patient outcomes in chronic lymphocytic leukemia (CLL); however, some patients experience adverse events (AEs) leading to discontinuation.
Awan, Farrukh T, Bibikova, Elena, Brown, Jennifer R, Byrd, John C, Charuworn, Prista, Frigault, Melanie M, Furman, Richard R, Hamdy, Ahmed, Hillmen, Peter, Izumi, Raquel, Linghu, Bolan, Pagel, John M, Patel, Priti, Schuh, Anna, Stephens, Deborah M, Wang, Min Hui, Woyach, Jennifer   +16 more
core   +1 more source

The role of time to first progression and fitness status in elderly patients with mantle cell lymphoma: Results from the ELDERLY MANTLE‐FIRST study

HemaSphere, Volume 9, Issue 12, December 2025.
Francesca Maria Quaglia, Annalisa Arcari, Lucia Morello, Luigi Marcheselli, Alessandra Tucci, Chiara Pagani, Valentina Bozzoli, Greta Scapinello, Francesco Piazza, Vittorio Ruggero Zilioli, Cristina Muzi, Benedetta Puccini, Benedetta Sordi, Maria Chiara Tisi, Nicolò Rampi, Alessia Castellino, Sara Veronica Usai, Jari Paternoster, Emanuele Cencini, Simone Ferrero, Chiara Consoli, Marco Basso, Elisa Lucchini, Elsa Pennese, Maria Elena Nizzoli, Michele Spina, Luca Pezzullo, Maria Stella De Candia, Rita Tavarozzi, Mauro Krampera, Carlo Visco   +30 more
wiley   +1 more source

Cardiotoxicity from bruton tyrosine kinase inhibitors (BTKi)—an analysis of an administrative health claims database

Cardio-Oncology
Background First generation Bruton tyrosine kinase inhibitors (BTKi) such as ibrutinib have been associated with cardiovascular toxicities. Newer generation BTKi (e.g.,acalabrutinib and zanabrutinib) have been associated with lower incidence of ...
Srilakshmi Vallabhaneni, Srinath Adusumalli, Jingyi Wu, Peter W. Groeneveld, James Gerson, Rupal P. O’Quinn   +5 more
doaj   +1 more source

Effect of Acalabrutinib in Combination with Bendamustine plus Rituximab on Survival Endpoints in Older Patients with Mantle Cell Lymphoma: Insights from the ECHO Trial

healthbook TIMES. Oncology Hematology
Mantle cell lymphoma (MCL) is a rare and often aggressive type of non-Hodgkin lymphoma that predominantly affects older adults and presents significant treatment challenges due to its clinical complexity and poor prognosis.
Adrian Schmidt
doaj   +1 more source